Assessment of bone marrow lymphocytic status during tyrosine kinase inhibitor therapy and its relation to therapy response in chronic myeloid leukaemia.

Summary, in English

Tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukaemia have been reported to induce immunomodulatory effects. We aimed to assess peripheral blood (PB) and bone marrow (BM) lymphocyte status at the diagnosis and during different TKI therapies and correlate it with treatment responses.

• Author: Mohamed El Missiry; Shady Adnan Awad; Hanna L Rajala; Ahmed Al-Samadi; Marja Ekblom; Berit Markevän; Ingbritt Åstrand-Grundström; Maren Wold; Ellen Rabben Svedahl; Birgitte Ravn Juhl; Ole Weis Bjerrum; Inger Haulin; Kimmo Porkka; Ulla Olsson-Strömberg; Henrik Hjorth-Hansen; Satu Mustjoki
• Publishing year: 2016-01-08
• Language: English
• Pages: 1041-1050
• Publication/Series: Journal of Cancer Research and Clinical Oncology
• Volume: 142
• Issue: 5
• Links: http://www.ncbi.nlm.nih.gov/pubmed/26746653?dopt=Abstract; http://dx.doi.org/10.1007/s00432-015-2101-4
• Document type: Journal article
• Publisher: Springer
• Topic: Hematology
• Status: Published
• ISBN/ISSN/Other: ISSN: 1432-1335